Warren Buffett gets a double take as the investment powerhouse settles on its first biotech investment

John Carroll

Editor & Founder

Coke. American-Express. Apple. And Biogen?

Warren Buffet’s Berkshire Hathaway, which made itself into a symbol of rock-solid investment strategy, has revealed a stake in the big biotech as it takes on one of the biggest gambles in the industry.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Warren Buffett gets a double take as the investment powerhouse settles on its first biotech investment

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

War­ren Buf­fett gets a dou­ble take as the in­vest­ment pow­er­house set­tles on its first biotech in­vest­ment

Editor & Founder

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Warren Buffett gets a double take as the investment powerhouse settles on its first biotech investment